Attralus Appoints James Testa as Vice President of Finance
February 10, 2022 08:00 ET
|
Attralus, Inc
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
December 13, 2021 08:00 ET
|
Attralus, Inc
AT-03 potently binds human AL and ATTR fibrils and is capable of binding diverse forms of systemic amyloid deposits in mouse models AT-03 enhances macrophage-mediated phagocytosis of AL amyloid...
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
November 04, 2021 09:00 ET
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus Closes $116 Million Series B Financing
September 08, 2021 07:00 ET
|
Attralus, Inc
- Proceeds to advance pipeline of transformational pan-amyloid removal (PAR) therapeutics into the clinic - Financing led by Logos Capital and included other leading public healthcare funds - ...
Attralus Appoints Jake Bauer to Board of Directors
July 28, 2021 07:00 ET
|
Attralus, Inc
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...